Article By:
TalkMarkets Newswire
Thursday, March 19, 2020 6:32 AM EDT
Soligenix announced positive preliminary top-line results for its pivotal Phase 3 FLASH trial evaluating SGX301 in the treatment of cutaneous T-cell lymphoma. The company will host an Investor Conference Call today at 8:30AM EDT,
In this article: SNGX